bevacizumab + triamcinolone acetonide — Competitive Intelligence Brief

bevacizumab + triamcinolone acetonide (bevacizumab + triamcinolone acetonide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor, Corticosteroid. Area: Oncology.

phase 3 Angiogenesis inhibitor, Corticosteroid VEGF-A Oncology Small molecule

Target snapshot

bevacizumab + triamcinolone acetonide (bevacizumab + triamcinolone acetonide) — Shahid Beheshti University of Medical Sciences. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while triamcinolone acetonide is a corticosteroid that reduces inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bevacizumab + triamcinolone acetonide TARGET	bevacizumab + triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	Angiogenesis inhibitor, Corticosteroid	VEGF-A
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor, Corticosteroid class)

1. Shahid Beheshti University of Medical Sciences · 1 drug in this class